Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 21;13(5):e9270.
doi: 10.5812/hepatmon.9270. Print 2013 May.

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial

Mohsen Razavizade  1 , Raika Jamali, Abbas Arj, Seyyed Mohammad Matini, Alireza Moraveji, Effat Taherkhani
Affiliations

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial

Mohsen Razavizade et al. Hepat Mon. .

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of insulin resistance (IR) syndrome. The effect of insulin sensitizers on liver function tests and metabolic indices in NAFLD patients is a matter of debate.

Objectives: The aim of study was to compare the effects of two different insulin sensitizers, pioglitazone, and metformin, on liver function tests (LFT), lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and liver fat content (LFC) in NAFLD patients.

Materials and methods: This double blind clinical trial was performed on patients who were referred to a gastroenterology clinic with evidence of fatty liver in ultrasonography. After excluding other causes, participants with persistent elevated alanine aminotransferase (ALT) levels and "NAFLD liver fat score" greater than -0.64 were presumed to have NAFLD and were enrolled. They were randomly assigned to take metformin (1 g/day) or pioglitazone (30 mg/day) for four months. Fasting serum glucose (FSG), ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), triglyceride, cholesterol (CHOL), high and low density lipoprotein (HDL, LDL), HOMA-IR, and LFC were checked at the baseline, two and four months post-treatment. LFC was measured by a validated formula.

Results: Eighty patients (68 males) with mean age of 35.27 (± 7.98) were included. After 2 months, LFT was improved significantly in the pioglitazone group and did not change in the metformin group. After four months, both medications significantly decreased serum levels of LFT, FSG, CHOL, LDL, HOMA-IR, and LFC, and increased serum level of HDL. No statistically significant differences were seen between the two treatment groups with regard to the changes of laboratory parameters and LFC from baseline to four months post-treatment.

Conclusions: During the four months, the use of metformin (1 g/day) and pioglitazone (30 mg/day) were safe and might have equally affected LFT, HOMA-IR, lipid profile, and LFC in NAFLD patients.

Keywords: Fatty Liver; Insulin Resistance; Metformin; Pioglitazone.

PubMed Disclaimer

References

    1. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012;11(1):18–27. - PubMed
    1. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon. 2012;12(10 HCC):e6023. doi: 10.5812/hepatmon.6023. - DOI - PMC - PubMed
    1. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007;6(6):572–8. - PubMed
    1. Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int. 2005;4(3):389–92. - PubMed
    1. Gharouni M, Rashidi A. Association between fatty liver and coronary artery disease: Yet to explore. Hepat Mon. 2007;2007(4, Autumn):243–44.

LinkOut - more resources